[Treatment of advanced testicular cancer].
Two patients with stage II, 12 patients with stage III advanced testicular cancer, were treated with a combination of CDDP, vinblastine and bleomycin. Four of the cases (28.6%) achieved a complete response and 6 (42.9%) achieved a partial response. The over all response rate was 71.4%. After CR, 2 cases (50%) showed relapse. Although the treatment confirms some efficacy of the drug regimen, the prognosis is poor in bulky metastasis. Early induction therapy with etoposide is necessary in cases of high volume metastasis.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001761:Bleomycin / Q000008:administration & dosage; D002945:Cisplatin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D004407:Dysgerminoma / Q000188:drug therapy; D006801:Humans; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000188:drug therapy; D011379:Prognosis; D013724:Teratoma / Q000188:drug therapy; D013736:Testicular Neoplasms / Q000188:drug therapy*; D014747:Vinblastine / Q000008:administration & dosage
D001761:Bleomycin; D014747:Vinblastine; D002945:Cisplatin